Skip to Content
US Videos

CVS: Underappreciated and Undervalued

The CVS-Aetna merger deal is significant, creating a powerful new company in the healthcare services company.


Vishnu Lekraj: Over the last handful of years there has been a major trend within the healthcare services space between the major conglomerates that occupy their supply chain. Currently we have CVS looking to purchase Aetna, and we have Cigna merging with Express Scripts. We believe these two deals are significant and could provide significant returns for investors over the longer term. These key pieces of the healthcare services supply chain will combine into one company that will provide several services on several different fronts from major constituencies within the healthcare space.

Right now, we'd like to highlight the CVS-Aetna merger as being a key piece of the strategy or key piece of this trend. We believe the new company will be a very powerful player as it will combine retail pharmacy, PBM, and health insurance into one company. We believe the invested capital returns will be significantly above the weighted average cost of capital for this company moving forward, and as a result, we believe CVS is underappreciated and undervalued at the moment.

Vishnu Lekraj does not own shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.